全球制药巨头中国区业绩披露!阿斯利康称王,默沙东暴跌66%,礼来狂飙18%...

中国医药创新促...
Mar 03

本文转载自赛柏蓝作者:草履虫随着2025年全球制药巨头财报季的结束,跨国药企(MNC)在中国市场的业绩表现已基本清晰。根据已披露的数据,7家MNC在中国区的制药业务总收入约为241亿美元,较2024年的262.76亿美元和2023年的261.74亿美元出现明显下滑。这一变化主要受到默沙东HPV疫苗佳达修(Gardasil)销量骤降的影响。从排名来看,阿斯利康以66.54亿美元继续稳居首位,诺华、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10